PN WI-NRS Efficacy Results | DUPIXENT® (dupilumab)

PRIME

Itch improvement was
observed at Week 4

Proportion (%) of patients with ≥4-point
improvement in WI-NRS

60%

≈3x AS MANY
PATIENTS
IMPROVED
(P<0.001)

18%

DUPIXENT 300 mg Q2W (n=75) Placebo (n=76) Nominal P value

^a Baseline WI-NRS scores: 8.6 (SD, 0.9) for DUPIXENT, 8.3 (SD, 1.1) for placebo.

A nominal difference was observed at Week 4 (19% with DUPIXENT vs 4% with placebo)³

Definitive conclusions cannot be made for results earlier than 24 weeks in PRIME. Data were not multiplicity controlled.

PRIME2

A nominal difference was observed at Week 11 (33% with DUPIXENT vs 17% with placebo), with a significantly greater proportion of DUPIXENT patients achieving a meaningful response at Week 12 (37% with DUPIXENT vs 22% with placebo; P=0.022, primary endpoint). At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo (P<0.001, secondary endpoint)^1-3

Definitive conclusions cannot be made for results at timepoints other than Week 12 and 24 in PRIME2. Data were not multiplicity controlled.

POOLED ANALYSIS:
PRIME AND PRIME2

Itch improvement observed after first dose (as measured at Week 2)

7.9%

of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 2 vs 1.9% with placebo⁴

59%

of DUPIXENT patients had ≥4-point improvement in WI-NRS at Week 24 vs 19% with placebo⁴

Definitive conclusions cannot be made for these results as the data were not multiplicity controlled and P values were nominal.

Explore NODULE CLEARANCE

IGA PN-S, Investigator’s Global Assessment PN-Stage; Q2W, once every 2 weeks; SD, standard deviation; WI-NRS, Worst Itch numerical rating scale.

Thinking about prescribing DUPIXENT? Find the
information you need to get started.